Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The FDA has approved uses of the targeted therapy crizotinib (Xalkori®) for patients with advanced lung cancer whose tumors have alterations in the ROS1 gene.
-
High-powered intravital microscopy reveals that 50 percent of blood vessels in melanoma tumors do not have any blood flow, according to a new study.
-
Research results sometimes outrace the design of an ongoing clinical trial and the trial has to be recalibrated to include newer treatments, according to NCI’s Dr. Jo Anne Zujewski.
-
NCI scientists have developed a novel strategy for identifying immune cells circulating in the blood that recognize specific proteins on tumor cells, a finding they believe may have potential implications for immune-based therapies.
-
Infection with human papillomavirus (HPV) types targeted by the quadrivalent HPV vaccine has declined by nearly two-thirds among teenage girls since HPV vaccination was recommended in the United States.
-
Quality biospecimens are a foundational resource for cancer research. One of NCI’s longest running biospecimen programs is the Cooperative Human Tissue Network, a resource mainly for basic discovery and early translational research.
-
Testing for genetic mutations strongly associated with an increased risk of breast cancer has risen dramatically among women younger than age 40 who are diagnosed with the disease, according to a new study.
-
Patients who miss radiation therapy sessions during cancer treatment have an increased risk of their disease returning, even if they eventually complete their course of radiation treatment, according to a new study.
-
Researchers have used a new zebrafish model of cancer to characterize the early genetic changes associated with the initiation of tumors.
-
Researchers have identified a genetic rearrangement that may drive the development of a rare benign brain tumor in children through three distinct biological mechanisms simultaneously.